QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.094409v1 316/2/772    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ko, M. C. H. Articles by Traynor, J. R. Search for Related Content PubMed PubMed Citation Articles by Ko, M. C. H. Articles by Traynor, J. R.

BEHAVIORAL PHARMACOLOGY

Differential in Vivo Potencies of Naltrexone and 6-Naltrexol in the Monkey

Department of Pharmacology, University of Michigan, Medical School, Ann Arbor, Michigan (M.C.H.K., M.F.D., J.H.W., J.R.T.); and Department of Anesthesiology and Pain Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea (H.L.)

6-Naltrexol is the major metabolite of the opioid receptor antagonist, naltrexone, in humans. However, there are no functional studies of 6-naltrexol in primates. The aim of this study was to compare the in vitro and in vivo potencies of naltrexone and 6-naltrexol in rhesus monkeys. Affinity and potency were determined using radioligand displacement and stimulation of 5'-O-(3-[³⁵S]thio)triphosphate ([³⁵S]GTPS) binding in monkey brain membranes. In vivo apparent pA₂ analysis was applied to compare the µ-opioid receptor (MOR) antagonist potency of both compounds in nondependent monkeys. In addition, the potencies of both compounds were determined in precipitating withdrawal manifested by increased respiratory parameters in acute morphine-dependent monkeys. In vitro assays revealed that naltrexone displayed 2-fold higher affinity and potency than 6-naltrexol for the MOR binding site and for MOR agonist-stimulated [³⁵S]GTPS binding, respectively. 6-Naltrexol (0.32-3.2 mg/kg) dose-dependently produced parallel rightward shifts of the dose-response curve of alfentanil-induced antinociception. Nevertheless, the apparent pA₂ value of 6-naltrexol (6.5) was 100-fold less potent than that of naltrexone (8.5) determined previously. 6-Naltrexol was also less potent than naltrexone in antagonizing other MOR-mediated effects including respiratory depression and itch/scratching. Naltrexone (0.0032-0.032 mg/kg) and 6-naltrexol (0.32-3.2 mg/kg) retained the same potency difference in precipitating withdrawal to a similar degree. Furthermore, 6-naltrexol failed to block naltrexone-precipitated withdrawal in morphine-dependent monkeys. These results indicate that naltrexone and 6-naltrexol display similar pharmacological actions with a large in vivo potency difference in monkeys such that 6-naltrexol may play a minimal role in the therapeutic or antagonist effects of naltrexone in primates.

Address correspondence to: Dr. M. C. Holden Ko, Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632. E-mail: mko{at}umich.edu

This article has been cited by other articles:

				S. Sirohi, S. V. Dighe, P. A. Madia, and B. C. Yoburn The Relative Potency of Inverse Opioid Agonists and a Neutral Opioid Antagonist in Precipitated Withdrawal and Antagonism of Analgesia and Toxicity J. Pharmacol. Exp. Ther., August 1, 2009; 330(2): 513 - 519. [Abstract] [Full Text] [PDF]

				M. C. H. Ko, H. Wei, J. H. Woods, and R. T. Kennedy Effects of Intrathecally Administered Nociceptin/Orphanin FQ in Monkeys: Behavioral and Mass Spectrometric Studies J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1257 - 1264. [Abstract] [Full Text] [PDF]